112 related articles for article (PubMed ID: 15203994)
1. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Novitzky N; Thomas V; Hale G; Waldmann H
Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
[TBL] [Abstract][Full Text] [Related]
2. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
3. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
5. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
6. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
7. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
8. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
9. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.
Novitzky N; Thomas V; Hale G; Waldmann H
Bone Marrow Transplant; 2005 Oct; 36(8):675-82. PubMed ID: 16113675
[TBL] [Abstract][Full Text] [Related]
11. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
12. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
Novitzky N; Thomas V; du Toit C; McDonald A
Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
[TBL] [Abstract][Full Text] [Related]
14. In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.
Novitzky N; Thomas V; du Toit C; Mcdonald A
Biol Blood Marrow Transplant; 2008 Jun; 14(6):709-18. PubMed ID: 18489997
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
[TBL] [Abstract][Full Text] [Related]
16. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
[TBL] [Abstract][Full Text] [Related]
17. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
[TBL] [Abstract][Full Text] [Related]
18. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
[TBL] [Abstract][Full Text] [Related]
19. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
[TBL] [Abstract][Full Text] [Related]
20. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
